NASH
NASH is the inflammatory, progressive form of NAFLD that can lead to cirrhosis. GLP-1 medications are becoming a cornerstone of NASH treatment.
NASH resolution
40-60%
Fibrosis improvement
20-40%
Progression prevention
Significant
Condition Guide
NASH
NASH Treatment Benefits
NASH involves liver inflammation and damage beyond simple fat accumulation. GLP-1 medications resolve NASH in 40-60% of patients. They reduce liver fat, inflammation, and fibrosis markers. Tirzepatide shows particular promise for NASH resolution. Weight loss of 7-10% is the primary treatment target. GLP-1s achieve this consistently while improving metabolic health. They may prevent progression to cirrhosis and liver cancer.
Monitoring and Care
Liver specialists should monitor NASH treatment. Repeat FibroScan or imaging at 12 months. Liver enzymes typically normalize within 3-6 months. Biopsy may be repeated after 18-24 months to confirm resolution. SeraVia Detox+ Shield supports liver health.
Frequently Asked Questions
Can GLP-1s reverse NASH?
Yes, studies show 40-60% of patients achieve NASH resolution with sustained weight loss. They may also improve fibrosis.
SeraVia Detox+ Shield provides liver-supporting nutrients for NASH patients on GLP-1 therapy.
Learn More →Find NASH specialists
Compare pricing, reviews, and availability across 18,000+ GLP-1 providers.
Search Providers →Explore all conditions
Learn how GLP-1 medications treat different conditions — from diabetes to PCOS to cardiovascular disease.